Kairos Pharma公司公布转移性去势抵抗性前列腺癌药物ENV-105（carotuximab）临床试验积极安全性结果后，其股价应声大涨。
周二该股飙升67%至1.15美元，单日成交量飙升至2.208亿股，较65日均量838,461股呈现爆发式增长。尽管如此，年内累计跌幅仍达24%。
中期安全性分析显示，这款处于II期临床阶段的药物与标准激素疗法阿帕鲁胺联用时耐受性良好。公司声明强调："迄今未报告剂量限制性毒性或非预期不良事件，治疗相关副作用可通过标准支持性护理有效控制。"
振奋人心的不仅是安全性数据——治疗潜力同样值得期待。研究人员观察到部分患者前列腺特异性抗原水平显著下降，个别病例甚至出现肿瘤缩小。这些早期信号暗示ENV-105可能具备双重抗肿瘤机制。
投资者目光已聚焦于九月即将揭晓的中期疗效数据。若疗效数据持续向好，这款靶向内皮素受体的创新疗法或将成为前列腺癌治疗领域的新锐力量。市场正密切关注后续进展，股价波动或将持续放大。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.